approval · primary record
LEBRIKIZUMAB-LBKZ
FDA · BLA · 2026-06-09
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2026-06-09 |
| Approval events | 1 |
| Brand | EBGLYSS |
| Sponsor | ELI LILLY AND CO |
| Route | INJECTION |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-06-09 | FDA | BLA | EBGLYSS | ELI LILLY AND CO | INJECTION |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:16.027Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:lebrikizumab-lbkz
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lebrikizumab-Lbkz · compound